Citations

Clear

4847 citation(s) found for "Tu, Eric".

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study
Cohen, Mikaël , Thomel-Rocchi, Océane, Sıva, Aksel , Okuda, Darin T. , Karabudak, Rana , Terzi, Murat , Carra‐Dallière, Clarisse , Durand‐Dubief, Françoise , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Casez, Olivier , Moreau, Thibault, Neau, Jean‐Philippe, Pelletier, Daniel , Kantarci, Orhun H. , Tütüncü, Melih , Derache, Nathalie, Bensa, Caroline , Louapre, Céline , Benoit, Jeanne , Landes-Château, Cassandre , Carra Dallière, Clarisse , Thouvenot, Eric , Ciron, Jonathan , Lebrun‐Frénay, Christine , Siva, Aksel , Durand-Dubief, Françoise , Okuda, Darin T , Cohen, Mikaël , Efendi, Hüsnü , Zéphir, Hélène , Bourre, Bertrand , Casez, Olivier , Seze, Jerome De

Mayo Clinic

Multiple Sclerosis Journal | June 16, 2023 | Volume: 29 | Issue: 9 | Pages: 1099-1106

10.1177/13524585231179669 | PMID 37322880 Get It

Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.
Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry
Crotti, Lia , Spazzolini, Carla , Nyegaard, Mette , Overgaard, Michael T. , Kotta, Maria‐Christina , Dagradi, Federica , Sala, Luca , Aiba, Takeshi , Ayers, Mark D. , Barc, Julien , Beach, Cheyenne M. , Behr, Elijah R. , Bos, J. Martijn , Covi, Peter, Donner, Birgit , Elbert, Adrienne , Eliasson, Håkan , Etheridge, Susan P. , Fukuyama, Megumi , Girolami, Francesca , Hamilton, Robert M. , Horie, Minoru , Iascone, Maria , Jiménez‐Jáimez, Juan , Jensen, Henrik Kjærulf , Kannankeril, Prince J. , Kaski, Juan Pablo , Makita, Naomasa , Muñoz‐Esparza, Carmen , Ohno, Seiko , Papagiannis, John , Porretta, Alessandra Pia , Prandstetter, C. , Probst, Vincent , Robyns, Tomas , Rosés‐Noguer, Ferran , Singh, Anoop , Spentzou, Georgia , Stute, Fridrike , Tfelt‐Hansen, Jacob , Till, Jan , Tobert, Kathryn E. , Webster, Gregory , Wilde, Arthur A.M. , Wolf, Cordula M. , Ackerman, Michael J. , Schwartz, Peter J. , Baban, Anwar , Barc, Julien , Beach, Cheyenne M , Behr, Elijah Raphael , Bos, Johan M , Cerrone, Marina , Cuneo, Bettina , Denjoy, Isabelle , Donner, Birgit , Elbert, Adrienne , Eliasson, Håkan , Etheridge, Susan P , Fukuyama, Megumi , Girolami, Francesca , Hamilton, Robert , Horie, Minoru , Iascone, Maria , Jiménez-Jaimez, Juan , Jensen, Henrik Kjærulf , Kannankeril, Prince J , Kaski, Juan P , Makita, Naomasa , Muñoz-Esparza, Carmen , Odland, Hans H , Ohno, Seiko , Papagiannis, John , Porretta, Alessandra Pia , Prandstetter, Christopher , Probst, Vincent , Robyns, Tomas , Rosenthal, Eric , Rosés-Noguer, Ferran , Sekarski, Nicole , Singh, Anoop , Spentzou, Georgia , Stute, Fridrike , Tfelt-Hansen, Jacob , Till, Jan , Vinocur, Jeffrey M , Webster, Gregory , Wilde, Arthur A M , Wolf, Cordula M , Ackerman, Michael J , Schwartz, Peter J. , Crotti, Lia , Kotta, Maria-Christina , Sala, Luca , Dagradi, Federica , Spazzolini, Carla , Aiba, Takeshi , Ayers, Mark D , Baban, Anwar , Cerrone, Marina , Cuneo, Bettina F. , Denjoy, Isabelle , Odland, Hans Henrik , Sekarski, Nicole , Vinocur, Jeffrey M.

Mayo Clinic

European Heart Journal | June 15, 2023 | Volume: 44 | Issue: 35 | Pages: 3357-3370

10.1093/eurheartj/ehad418 | PMID 37528649 Get It

Abstract Aims Calmodulinopathy due to mutations in any of the three CALM genes (CALM1–3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. Methods and results The ICalmR is an international, collaborative, observational study, assembling and analysing clinical and genetic data on CALM-positive patients. The ICalmR has enrolled 140 subjects (median age 10.8 years [interquartile range 5–19]), 97 index cases and 43 family members. CALM-LQTS and CALM-CPVT are the prevalent phenotypes. Primary neurological manifestations, unrelated to post-anoxic sequelae, manifested in 20 patients. Calmodulinopathy remains associated with a high arrhythmic event rate (symptomatic patients, n = 103, 74%). However, compared with the original 2019 cohort, there was a reduced frequency and severity of all cardiac events (61% vs. 85%; P = .001) and sudden death (9% vs. 27%; P = .008). Data on therapy do not allow definitive recommendations. Cardiac structural abnormalities, either cardiomyopathy or congenital heart defects, are present in 30% of patients, mainly CALM-LQTS, and lethal cases of heart failure have occurred. The number of familial cases and of families with strikingly different phenotypes is increasing. Conclusion Calmodulinopathy has pleiotropic presentations, from channelopathy to syndromic forms. Clinical severity ranges from the early onset of life-threatening arrhythmias to the absence of symptoms, and the percentage of milder and familial forms is increasing. There are no hard data to guide therapy, and current management includes pharmacological and surgical antiadrenergic interventions with sodium channel blockers often accompanied by an implantable cardioverter–defibrillator.
Abstract 10822: Familial Hypercholesterolemia in the EMERGE Network: 1-Year Outcomes After Return of Results
Kochan, David C., Perez, Emma , Anderson, Katherine , Salvati, Zachary , Hebbring, Scott J. , Gibbs, Richard A. , Linder, Jodell E. , Roden, Dan M. , Manolio, Teri A. , Sherafati, Alborz , Dikilitas, Ozan , Saadatagah, Seyedmohammad , Satterfield, Benjamin A. , Jones, Laney K , Sharp, Richard R. , Sturm, Amy C. , Zouk, Hana , Venner, Eric , Chung, Wendy K. , Peterson, Josh F. , Jarvik, Gail P. , Rehm, Heidi L. , Roden, Dan M. , Williams, Marc S , Kullo, Iftikhar J.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10822 Get It

Introduction: Relatively little is known about outcomes following return of secondary findings detected in large scale sequencing projects. We assessed 1-year outcomes following return of pathogenic/likely pathogenic (P/LP) variants associated with familial hypercholesterolemia (FH) in phase III of the eMERGE network (2015-2019). Methods: Adult participants (n=18,544) at 7 sites were enrolled in a prospective cohort study to study the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . Process, intermediate, and/or clinical outcomes within 1-year after return of results (RoR) were ascertained by electronic health record (EHR) review. A process outcome was defined as referral to a specialist or ordering new tests, including lipid profile and screening tests for coronary heart disease. An intermediate outcome was defined as new diagnosis of FH or atherosclerotic cardiovascular disease. A clinical outcome was defined as initiation or change in lipid-lowering medication. The primary outcomes were a new diagnosis of FH and modification of lipid lowering therapy. Results: Results were returned to 134 individuals, and data for 119 participants were available for the outcomes analysis. Process (86%), intermediate (49%), and/or clinical (26%) outcomes occurred in 92% of participants. Process outcomes included 72% with new tests ordered and 61% referred to a specialist. Before RoR, 86.5% of individuals with FH associated P/LP variants had a diagnosis of hypercholesterolemia but only 17.6% had a diagnosis of FH; 89% were on a statin but only 58% were on a high intensity statin. Following RoR, 44% (52/119) received a new diagnosis of FH. Lipid lowering treatment was modified in 26% (31/119), including initiation of a statin in 5%, increasing statin dose in 13%, and adding ezetimibe or a PCSK9 inhibitor in 12.6%. Conclusions: In a multisite cohort of EHR-linked biobanks, monogenic FH was underdiagnosed (only 17.6% had a specific diagnosis) and undertreated (only 58% were on a high intensity statin); 44% of participants received a new diagnosis of FH and 26% had lipid lowering treatment modified after RoR. These results highlight the clinical utility of returning FH variants in EHR-linked biobanks.
Performance of Nuclear Magnetic Resonance-Based Estimated Glomerular Filtration Rate in a Real-World Setting
Santamaría, Amauri Schwäble , Grassi, M , Meeusen, Jeffrey W. , Lieske, John C. , Scott, Renee, Robertson, Andrew, Schiffer, Eric, Schwäble Santamaria, Amauri , Grassi, Marcello , Lieske, John C

Mayo Clinic

Bioengineering | June 14, 2023 | Volume: 10 | Issue: 6 | Pages: 717

10.3390/bioengineering10060717 | PMID 37370648 Get It

An accurate estimate of glomerular filtration rate (eGFR) is essential for proper clinical management, especially in patients with kidney dysfunction. This prospective observational study evaluated the real-world performance of the nuclear magnetic resonance (NMR)-based GFRNMR equation, which combines creatinine, cystatin C, valine, and myo-inositol with age and sex. We compared GFRNMR performance to that of the 2021 CKD-EPI creatinine and creatinine-cystatin C equations (CKD-EPI2021Cr and CKD-EPI2021CrCys), using 115 fresh routine samples of patients scheduled for urinary iothalamate clearance measurement (mGFR). Median bias to mGFR of the three eGFR equations was comparably low, ranging from 0.4 to 2.0 mL/min/1.73 m2. GFRNMR outperformed the 2021 CKD-EPI equations in terms of precision (interquartile range to mGFR of 10.5 vs. 17.9 mL/min/1.73 m2 for GFRNMR vs. CKD-EPI2021CrCys; p = 0.01) and accuracy (P15, P20, and P30 of 66.1% vs. 48.7% [p = 0.007], 80.0% vs. 60.0% [p < 0.001] and 95.7% vs. 86.1% [p = 0.006], respectively, for GFRNMR vs. CKD-EPI2021CrCys). Clinical parameters such as etiology, comorbidities, or medications did not significantly alter the performance of the three eGFR equations. Altogether, this study confirmed the utility of GFRNMR for accurate GFR estimation, and its potential value in routine clinical practice for improved medical care.
Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Huseman, Eric D. , Lo, Anna , Fedorova, Olga , Elia, James L. , Gueble, Susan , Lin, Kingson , Sundaram, Ranjini K. , Oh, Joonseok , Rees, Matthew G. , Batista, Víctor S. , Crawford, Jason M. , Pyle, Anna Marie , Burgenske, Danielle M. , Liu, Jinchan , Menges, Fabian , Ronan, Melissa M. , Roth, Jennifer A. , Sarkaria, Jann N. , Bindra, Ranjit S. , Herzon, Seth B.

Mayo Clinic

No container title available | June 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv-2023-zwj94 Get It

Glioblastoma (GBM) is a lethal brain cancer with a five-year survival rate of <5%. Approximately half of GBM tumors lack the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT), which reverses O6-alkylguanine (O6G) lesions. Patients presenting MGMT– GBM are treated with surgery followed by radiation therapy and temozolomide (TMZ), an imidazotetrazine prodrug that produces O6-methylguanine (O6MeG) lesions. However, ~50% of these patients will develop TMZ resistance by silencing of the DNA mismatch repair (MMR) pathway. We recently reported that the novel N3-(2-fluoroethyl)imidazotetrazine “KL-50” is efficacious and well-tolerated in murine models of TMZ-resistant GBM (Lin et al. Science 2022, 377, 502). Herein, we rigorously establish that KL-50 generates DNA interstrand crosslinks (ICLs) by DNA alkylation to generate O6-(2-fluoroethyl)guanine (O6FEtG), displacement of fluoride to form an N1,O6-ethanoguanine (N1,O6EtG) intermediate, and ring-opening by the adjacent cytidine. 2-Chloroethylating agents, such as lomustine and mitozolomide (MTZ), generate the same ICL by an analogous mechanism. However, DNA ICLs form >10-fold more slowly from O6FEtG than O6ClEtG, and this slower rate of cross-linking allows MGMT to reverse the initial O6FEtG in healthy tissue while also reducing MGMT–DNA cross-links arising from addition of MGMT to the N1,O6EtG intermediate. KL- 50 is efficacious in an intracranial patient-derived murine xenograft of TMZ-resistant, MGMT–/MMR– GBM (mOS = 205, 28, and 26 d for KL-50, TMZ, and vehicle-treated control, respectively) and in murine models of newly-diagnosed MGMT–/MMR+ GBM, suggesting its use in recurrent and up-front settings, respectively. These studies underscore the significance of considering the rates of chemical DNA modification and biochemical DNA repair in the design of systemic DNA alkylation agents.
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Algieri, Frankie, Gurski, Lisa A., Stehman, Katie, Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Hubbard, Joleen M. , Hussan, Hisham , Jeck, William R. , Miller, Eric D. , Parikh, Aparna R. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John , Williams, Grant R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 12, 2023 | Volume: 21 | Issue: 6 | Pages: 653-677

10.6004/jnccn.2023.0030 | PMID 37308125 Get It

This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Bates, James E. , Shrestha, Suman , Liu, Qi , Smith, Susan A. , Mulrooney, Daniel A. , Leisenring, Wendy M. , Robison, Leslie L. , Chow, Eric J. , Oeffinger, Kevin C. , Armstrong, Gregory T. , Howell, Rebecca M. , Leisenring, Wendy , Gibson, Todd , Robison, Leslie L , Chow, Eric J , Oeffinger, Kevin C , Constine, Louis S , Hoppe, Bradford S , Lee, Choonsik , Yasui, Yutaka , Mulrooney, Daniel A , Gibson, Todd M. , Hoppe, Bradford S.

Mayo Clinic

Journal of Clinical Oncology | June 12, 2023 | Volume: 41 | Issue: 22 | Pages: 3826-3838

10.1200/jco.22.02320 | PMID 37307512 Get It

PURPOSE Radiation-associated cardiac disease is a major cause of morbidity/mortality among childhood cancer survivors. Radiation dose-response relationships for cardiac substructures and cardiac diseases remain unestablished. METHODS Using the 25,481 5-year survivors of childhood cancer treated from 1970 to 1999 in the Childhood Cancer Survivor Study, we evaluated coronary artery disease (CAD), heart failure (HF), valvular disease (VD), and arrhythmia. We reconstructed radiation doses for each survivor to the coronary arteries, chambers, valves, and whole heart. Excess relative rate (ERR) models and piecewise exponential models evaluated dose-response relationships. RESULTS The cumulative incidence 35 years from diagnosis was 3.9% (95% CI, 3.4 to 4.3) for CAD, 3.8% (95% CI, 3.4 to 4.2) for HF, 1.2% (95% CI, 1.0 to 1.5) for VD, and 1.4% (95% CI, 1.1 to 1.6) for arrhythmia. A total of 12,288 survivors (48.2%) were exposed to radiotherapy. Quadratic ERR models improved fit compared with linear ERR models for the dose-response relationship between mean whole heart and CAD, HF, and arrhythmia, suggesting a potential threshold dose; however, such departure from linearity was not observed for most cardiac substructure end point dose-response relationships. Mean doses of 5-9.9 Gy to the whole heart did not increase the risk of any cardiac diseases. Mean doses of 5-9.9 Gy to the right coronary artery (rate ratio [RR], 2.6 [95% CI, 1.6 to 4.1]) and left ventricle (RR, 2.2 [95% CI, 1.3 to 3.7]) increased risk of CAD, and to the tricuspid valve (RR, 5.5 [95% CI, 2.0 to 15.1]) and right ventricle (RR, 8.4 [95% CI, 3.7 to 19.0]) increased risk of VD. CONCLUSION Among children with cancer, there may be no threshold dose below which radiation to the cardiac substructures does not increase the risk of cardiac diseases. This emphasizes their importance in modern treatment planning.
Abstract 556: Bystander effects of EGFR-targeting 40H3 antibody-drug conjugates in glioblastoma with heterogeneous EGFR expression
Ho, Eric , Porath, Kendra A. , Antignani, Antonella , Fitzgerald, David , Jain, Sonia , Sarkaria, Jann N.

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 556-556

10.1158/1538-7445.am2023-556 Get It

Abstract An important aspect to determine the efficacy of a targeted macromolecule in treating brain tumors is penetration and activity in tumor across a heterogeneously intact blood-brain barrier. In this study, novel epidermal growth factor receptor (EGFR)-targeted antibody drug conjugates (ADCs) were constructed with a focus on cytotoxicity in glioblastoma (GBM) with an EGFR heterogeneous cell population. Initially, the cytotoxicity of free payloads with multiple mechanisms of cell kill was assessed. These included tesirine (TS, induces DNA cross-links), deruxtecan (Dxd) and SN38 (inhibit topoisomerase I), and an auristatin (MMAE) and maytansinoid (DM1) (inhibit microtubule polymerization). Across four GBM PDXs with varied EGFR expression (GBM6, 39 and 108- EGFRviii amplified; GBM10 - non-amplified), free TS and MMAE were consistently potent with EC50 values ranging from 0.50-45.9 pM and 7.9-229.1 pM, respectively. In contrast, the other free toxins were less potent; EC50 values: Dxd, 0.21-13.1 nM; SN38, 0.87-5.6 nM; DM1, 2.1-19.9 nM. Based on these results, the 40H3 EGFR-specific IgG was used to construct ADCs with TS and MMAE. 40H3-TS had a drug:antibody ratio (DAR) of 2.5 and was potently cytotoxic in GBM6, GBM39 and GBM108, while minimal cytotoxicity was observed in GBM10 or normal astrocyte SVG-A cells. 40H3-MMAE had a DAR of 3 and was similarly effective in GBM6 and GBM39 but less potent in GBM108, GBM10, and SVG-A. Bystander cytotoxicity was evaluated U87 cells expressing eGFP/fLuc2 (U87eGFP/fluc2) or EGFRviii (U87EGFRviii). Using live-cell imaging, U87EGFRviii cells treated with 40H3-TS or 40H3-MMAE had significantly reduced cell confluence relative to control. The same drug treatments in U87eGFP/fLuc2 cells had no effect on growth/confluence. However, in a 1:1 mixed culture, overall confluence was reduced from 89% in control to 35% and 32% after 40H3-TS (p&lt;0.0001) or 40H3-MMAE (p&lt;0.0001) treatment, respectively. This bystander killing of U87eGFP/fLuc2 cells was indicated by a reduction in confluence of green-fluorescent cells from 50% in control versus 29% with 40H3-TS (p&lt;0.0001) and 26% with 40H3-MMAE (p&lt;0.0001) treatment. In GBM39 orthotopic tumors, a single infusion of 10 or 20 µg 40H3-TS via convection enhanced delivery (CED) reduced the bioluminescence signal 7 days post treatment by ~10-fold (p=0.03) as compared to 40H3 control. However, 50% and 80% mortality was observed within a week of infusing 10 and 20 µg 40H3-TS, respectively. Neurotoxicity was associated with neuron loss in treated hemisphere as determined by NeuN staining. In summary, these data highlight the potential for novel EGFR-targeted ADCs to provide potent direct and bystander cytotoxicity to GBM cells. However, further selection and optimization of the conjugated toxins will be required to balance potency and bystander killing with toxicity for EGFR-targeted ADCs. Citation Format: Sonia Jain, Eric Chun Ho, Kendra A. Porath, Antonella Antignani, David J. FitzGerald, Jann N. Sarkaria. Bystander effects of EGFR-targeting 40H3 antibody-drug conjugates in glioblastoma with heterogeneous EGFR expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 556.
Abstract 6624: 3D assessment of the lung cancer microenvironment using multi-resolution open-top light-sheet microscopy
Alvarsson, Alexandra , Storey, Carl, Pope, Brandy Olin, Tufariello, Jessica, Bungum, Aaron O., Chan, Cheuk Ki, Edell, Eric S. , Hartley, Christopher , Reisenauer, Janani , Reder, Nicholas P. , Stoltzfus, Caleb R. , Vierkant, Robert A. , Tufariello, Jessica A., Naso, Julia , Chan, C., Hartley, Christopher P

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 6624-6624

10.1158/1538-7445.am2023-6624 Get It

Abstract Background: Non-small cell lung cancer (NSCLC) tissue is a valuable resource for diagnosis, treatment planning, and drug development. Current 2D histopathological techniques introduce under-sampling error (i.e., a single 5 um section represents 0.5% of a 1 mm thick biopsy), interobserver variability, and fail to capture the biology contained within the entire tissue sample. We have developed a suite of technologies to stain, chemically clarify, image, visualize, and analyze entire intact NSCLC tissue samples. Methods: Human NSCLC tissue, stored frozen in OCT, was fixed in 4% paraformaldehyde, stained with nuclear (TOPRO-3) and general protein (Eosin) fluorescent dyes, and optically cleared using a modified iDISCO protocol with ethyl cinnamate as the refractive index matching solution. Whole, intact tissue samples, roughly 1-5mm3 in volume, were imaged at 2 microns/pixel resolution with an open-top light-sheet microscope (3Di, Alpenglow Biosciences). Smaller regions of interest (ROIs) with key pathologic features were reimaged at higher resolution, 0.17 microns/pixel, to reveal subnuclear features and for cell typing. Visualization was performed using Aivia software. Results: NSCLC tissue samples were successfully imaged in 3D. Low resolution images (2 microns/pixel) were obtained within 4-31 minutes, depending on the tissue volume. The 3D distribution of cancer cells, immune cells, vessels, and fibrosis varied substantially throughout the volume of the tissue. Recognizable histologic features, including nests of tumor cells surrounded by vasculature and immune cells, were readily visualized. Squamous and adenocarcinoma with its subtypes (solid, acinar, lepidic, and micropapillary) morphologies were recognizable in 2D optical sections of the 3D datasets. Imaging quality degraded in tissue deeper than 1 mm due to light scattering. Conclusion: We assessed intact NSCLC tissue samples measuring up to 5 mm3 using our custom light-sheet microscope and tissue clearing techniques. This novel method enables us to visualize key features of NSCLC such as the tumor interfaces, tertiary lymphoid structures, vessels and fibrosis in the entire tissue sample, preventing under sampling error, and potentially enabling new biologic insights. Next steps include segmentation and quantification of key tissue structures such as tumor volume, immune cell distribution, and fibrosis/immune cell exclusion. This proof-of-concept study provides motivation for further investigation into the significance of 3D tissue features in NSCLC tissue samples. Citation Format: Alexandra Alvarsson, Carl Storey, Brandy Olin Pope, Caleb Stoltzfus, Robert Vierkant, Jessica Tufariello, Aaron Bungum, Julia Naso, Cheuk Ki Chan, Eric Edell, Christopher Hartley, Janani Reisenauer, Nicholas Reder. 3D assessment of the lung cancer microenvironment using multi-resolution open-top light-sheet microscopy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6624.